Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Parathyroid Glands00:59

The Parathyroid Glands

2.5K
The two pairs of parathyroid glands embedded within the posterior surface of the thyroid gland are restricted by a dense capsule around them. These glands comprise two distinct cell populations—parathyroid oxyphil and parathyroid principal cells- pivotal in calcium homeostasis.
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
2.5K
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

2.9K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
2.9K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

758
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
758
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

990
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
990
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

443
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
443
Skeleton and Calcium Homeostasis01:21

Skeleton and Calcium Homeostasis

4.8K
Calcium is not only the most abundant mineral in bone but also the most abundant mineral in the human body. Calcium ions are needed for bone mineralization, tooth health, heart rate regulation and strength of contraction, blood coagulation, the contraction of smooth and skeletal muscle cells, and the regulation of nerve impulse conduction. The average calcium level in the blood is about 10 mg/dL. When the body cannot maintain this level, a person will experience hypo or hypercalcemia.
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanosensitive TRPV4 immunohistochemistry improves deep learning-based classification of ductal carcinoma in situ beyond H&E morphology.

The journal of pathology. Clinical research·2026
Same author

Burnout Risk Among Providers of an Integrated Care Program Supporting Transitions Between the Hospital and Home: A Descriptive Mixed Methods Evaluation.

International journal of environmental research and public health·2026
Same author

Non-functioning adrenocortical carcinoma presenting as acute spontaneous retroperitoneal haemorrhage.

Endocrinology, diabetes & metabolism case reports·2026
Same author

A Prospective, Multicenter, Open-Label Assessment of Efficacy and Safety of the Quanta Dialysis System for Home Hemodialysis.

Kidney medicine·2026
Same author

A Parallel Group, 1:1 Randomised, Pilot Study Comparing the Clinical Efficacy and Bleeding Risk Between Low Dose and Standard Dose Intrapleural Tissue Plasminogen Activator for Adults With Pleural Infection.

Respirology case reports·2026
Same author

A 3-year prospective study to assess clinical characteristics and risk factors for exacerbations in patients with asthma-COPD overlap based on the GINA guideline compared with patients with asthma and COPD.

Respiratory research·2026

Related Experiment Video

Updated: Sep 11, 2025

Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation
07:13

Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation

Published on: March 14, 2017

14.7K

Durvalumab-Induced Hypoparathyroidism.

Christopher Chan1,2,3, Varun Manoharan1,2,4, Manimegalai Manoharan1,2,5

  • 1Diabetes and Endocrine Service, Liverpool Hospital, New South Wales, Australia.

AACE Endocrinology and Diabetes
|August 11, 2025
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitors (ICIs) can cause rare immune-related adverse events like hypoparathyroidism. This case highlights durvalumab-induced hypoparathyroidism, emphasizing the need for increased awareness and research into its mechanisms.

Keywords:
durvalumabhypoparathyroidismimmune checkpoint inhibitors

More Related Videos

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
03:57

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy

Published on: July 14, 2023

2.0K
Establishment of a Simple and Effective Rat Model for Intraoperative Parathyroid Gland Imaging
07:12

Establishment of a Simple and Effective Rat Model for Intraoperative Parathyroid Gland Imaging

Published on: August 17, 2022

3.8K

Related Experiment Videos

Last Updated: Sep 11, 2025

Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation
07:13

Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation

Published on: March 14, 2017

14.7K
Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
03:57

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy

Published on: July 14, 2023

2.0K
Establishment of a Simple and Effective Rat Model for Intraoperative Parathyroid Gland Imaging
07:12

Establishment of a Simple and Effective Rat Model for Intraoperative Parathyroid Gland Imaging

Published on: August 17, 2022

3.8K

Area of Science:

  • Oncology
  • Immunology
  • Endocrinology

Background:

  • Immune checkpoint inhibitors (ICIs) are increasingly used for cancer treatment, leading to a rise in immune-related adverse events.
  • Endocrinopathies are known adverse events, but ICI-induced hypoparathyroidism is exceptionally rare.

Observation:

  • A 64-year-old man developed symptomatic hypocalcemia two years post-durvalumab therapy for non-small cell lung cancer.
  • Laboratory findings revealed suppressed parathyroid hormone levels, persisting even after calcium correction.

Findings:

  • This case presents durvalumab-induced hypoparathyroidism, a rare immune-related adverse event.
  • The persistent hypoparathyroidism after immunotherapy cessation suggests an immune-mediated mechanism.

Implications:

  • Increased clinical awareness and recognition of durvalumab-induced hypoparathyroidism are crucial.
  • Further research is needed to elucidate the underlying mechanisms and explore potential management strategies.